Supporting Information

The Application of REDOR NMR to Understand the Conformation of Epothilone B

Spectral data for compounds 3, 7-10, 17, 18, 21, 23-25, 27, 29, 31, 32, 35-42, 45-48.

Figure *S*1. Synthesis of analog **3** and its intermediate compounds: (A) Synthesis of compound **25**, (B) Synthesis of compound **39**, (C) Synthesis of compound **11**, (D) Synthesis of compound **33**, (E) Synthesis of compound **47**, (F) Synthesis of compound **3**, (E) Synthesis of compound **20**.

Figure S2. TEM images of the analog **3**-bound microtubules. The scale bars represent 1 μ m (A) and 500 nm (B). Before collecting the TEM images, the lyophilized powder was resuspended in PEM buffer supplemented with 20 μ M epothilone B.

Figure S3. A schematic representation of the ${}^{2}H{}^{19}F{}$ REDOR sequence for a dephasing signal (*S*) at $4T_r$.

Figure S4. Solid-state ¹⁹F MAS NMR spectra of 2-fluoro-2-methyl-d₃-malonic acid ([2-F,2-Me-d₃]MA) lyophilized in pipes buffer.

Figure S5. The full-echo (S_0) and dephasing (S) spectra obtained by co-adding the most intense four spinning sidebands in the ²H{¹⁹F} REDOR spectra (Figure 5). The peak heights of the difference (ΔS) spectra and noise levels in parenthesis being marked on each spectrum in fractions of the corresponding full-echo spectra. The dipolar evolution times are marked on top in multiples of the rotor period (T_r).

Figure *S***6**. ²H{¹⁹F} REDOR dephasing curves for possible distance pairs (see also Table *S*2).

Figure S7. Hydrogen-bond interactions of polar atoms of the epothilone A conformer $epoA(TUB)_4i50$ with amino residues in tubulin dimer.

Figure S8. The cell viability assay curves for the [D,F]-labelled and natural epothilone B against human lung carcinoma (A549) and cervix adenocarcinoma (HeLa).

Compound ^a	Analog 3 -bound microtubules		[2-F,2-Me-d ₃]MA	
	mg	wt%	mg	wt%
Sucrose	60	59	-	-
Tubulin	40	39	-	-
Labeled compound ^b	0.18	< 1	9.5	11
Pipes	1.21 ^c	1	67.5	75
EGTA	0.02 ^c	< 1	-	-
MgCl ₂	0.01 ^c	< 1	-	-
K^+ ion	0.23 ^c	< 1	13 ^e	14
Water	20 ^d	17	-	-
Sum	122	100	90	100

Table S1. Constituents of the lyophilized powders for REDOR NMR

^aThe numbers are estimated values based on the reaction conditions.

^bThe labeled compound is either analog **3** or [2-F,2-Me-d₃]MA.

^cFrom tubulin assembly buffer entrapped in the microtubule pellet (see text).

^dBound water molecules (see text)

^eFrom KOH used for pH adjust


SIMPSON -	REDOR d	- RMSD ^a	
	Short	Long	- KWSD
Fit1	5.9	5.9	0.01
Fit2	5.6	6.2	0.01
Fit3	5.3	7.7	0.01
Fit4	5.0	7.7	0.01
Fit5	4.7	7.4	0.02

Table S2. SIMPSON calculations for possible distance pairs $(^{2}H^{-19}F)$ to fit the experimental data (see Figure S6)


^aroot-mean-square deviation from the experimental data

Figure S1. Lee et al.


(A) Synthesis of compound 25




(B) Synthesis of compound **39**




(C) Synthesis of compound 11




(D) Synthesis of compound 33





(E) Synthesis of compound 47



(F) Synthesis of compound **3**







trifluoride




Figure S2. Lee et al.




Fig. S3 Lee et al.




Figure S4. Lee et al.




Figure S5. Lee et al.




Figure S6. Lee et al.




Figure S7. Lee et al.




Figure S8. Lee et al.

